|
血小板源性生长因子受体基因重排的研究 |
| |
COOLS J，DeANGELO DJ，GOTLIB J，et a1．A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as fl therapeutic target of imatinib in idiopathic hypereosinophilic syndrome[J]． N Engl J M ed ，2003，348(13)：12011214．
[8] LIERMAN E, FOLENS C, STOVER EH, et al .Sorafenib is a potent inhibitor of FIP1L1PDGFRαand the imatinibresistant FIP1L1PDGFRαT674I mutant[J]. J Blood, 2006, 108(4):13741376.
[9] PARDANANI A, KETTERLING RP, STEPHANIE R, et al. CHIC2 deletion, a surrogate for FIP1L1PDGFRA fusion, occurs in systemicmastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy[J]. J Blood, 2003,102:30933096.
[10] ROMPAEY LV, POTTER M, ADAMS C, et al. Tel induces a G1 arrest and suppresses Rasinduced transformation[J]. Oncogene, 2000,19:52445250.
[11] WHEADON H , WELHAM M .The coupling of TEL/PDGFR to distinct functional responses is modulated by the presence of cytokine: involvement of mitogenactivated protein kinases[J]. J Blood, 2003 ,102:14801489.
[12] MAGNUS K. MAGNUSSON KE. Meade K E, et al. Rabaptin5 is a novel fusion partner to plateletderived growth factor b receptor in chronic myelomonocytic&上一页 [1] [2] [3] [4] [5] [6] 下一页
上一个医学论文： 腔静脉滤器保护下介入治疗深静脉血栓形成
下一个医学论文： 自发性脑出血患者血清MMP 9及TIMP 1水平的研究
|
|
|
您现在的位置： 绿色健康网 >> 医学论文 >> 内科论文 >> 正文